Innate immune activation via oil-in-water adjuvant

Oil-in-water emulsion adjuvants are proprietary mixtures (not single molecules) used in vaccines to boost immunogenicity by activating the innate immune response. They rapidly recruit phagocytes (monocytes, neutrophils, dendritic cells) and induce local chemokine production, promoting antigen uptake and migration to draining lymph nodes[1][2][3]. Typical formulations like MF59 (squalene-based) and AS03 (squalene plus α-tocopherol) have been extensively used in influenza and pandemic vaccines[3][5][6]. These adjuvants promote robust B and T cell responses by enhancing antigen presentation and the adaptive immune cascade, often via DAMP/PRR pathways but independently of canonical inflammasome (NLRP3) signaling[3][4][5]. They are not molecules, receptors, or genes in the conventional sense, but mechanisms embodied by multi-component excipients. Key point: This "target" does not represent a discrete molecular entity and should not be treated as a canonical single-molecule target. The entry is incorrect as a molecule/receptor, and no canonical abbreviation or gene/protein name applies[1][3][5].

Other names

Oil-in-water emulsion adjuvantMF59 (example)AS03 (example)squalene-based adjuvant

Acts as an antigen delivery system for *slow-release* in lymph nodes, enhancing antigen presentation[3][5]. - Activates innate immune cells (e.g., monocytes, dendritic cells, neutrophils) at the injection site and draining lymph node[1][3]. - Induces chemokine and cytokine secretion (e.g., CCL2, CCL3, IL-6, CXCL1), resulting in immune cell recruitment[5]. - Enhances formation of germinal centers and follicular helper T cells, boosting adaptive immune response[1][3]. - Triggers PRR (pattern recognition receptor) signaling via DAMPs, through NLRP3-independent and, variably, MyD88-dependent pathways[3][5].